UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: Linaclotide, a guanylate cyclase C agonist, has been shown in clinical trials to improve symptoms of irritable bowel syndrome with constipation (IBS-C). Here we report data from a real-world study of linaclotide in the UK. Methods: This 1-year, multicentre, prospective, observational study in the UK enrolled patients aged 18 years and over initiating linaclotide for IBS-C. The primary assessment was change from baseline in IBS Symptom Severity Scale (IBS-SSS) score at 12 weeks, assessed in patients with paired baseline and 12-week data. Change from baseline in IBS-SSS score at 52 weeks was a secondary assessment. Adverse events were recorded. Results: In total, 202 patients were enrolled: 185 (91.6%) were female, median age was 44.9 years (range 18.1–77.2) and 84 (41.6%) reported baseline laxative use. Mean (standard deviation) baseline IBS-SSS score was 339 (92), with most patients ( n = 129; 66.8%) classified as having severe disease (score ⩾300). In patients with paired data, there was a significant mean (95% confidence interval) decrease in IBS-SSS score from baseline to 12 weeks [−77.0 (−96.3, −57.7); p < 0.001; n = 124] and baseline to 52 weeks [−70.7 (−95.0, −46.5); p < 0.001; n = 76]. Overall, 174 adverse events were reported in 77 (38.1%) patients, most commonly diarrhoea ( n = 54; 26.7%), abdominal pain ( n = 21; 10.4%) and abdominal distension ( n = 13; 6.4%). Conclusion: Linaclotide significantly improved IBS-SSS score at 12 and 52 weeks. These results provide insights into outcomes with linaclotide treatment over 1 year in patients with IBS-C in real-world clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Lacy, B. E., Mearin, F., Chang, L., Chey, W. D., Lembo, A. J., Simren, M., & Spiller, R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.031 · Cited by 2,866
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Irritable Bowel Syndrome: A Clinical Review
Chey, W. D., Kurlander, J., & Eswaran, S. (2015) · JAMA · doi:10.1001/jama.2015.0954 · Cited by 1,081
Hungin, A. P. S., Whorwell, P. J., Tack, J., & Mearin, F. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01456.x · Cited by 781
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Chey, W. D., Lembo, A. J., Lavins, B. J., Shiff, S. J., Kurtz, C. B., Currie, M. G., MacDougall, J. E., Jia, X. D., Shao, J. Z., Fitch, D. A., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.254 · Cited by 463
Review article: the economic impact of the irritable bowel syndrome
Canavan, C., West, J., & Card, T. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12938 · Cited by 458
Research works printed but not linked: 1
- Emmanuel A, 2016, United European Gastroenterol J, 4, A295
Cited by
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Self-citationIrritable bowel syndrome: diagnosis and management
Masuy, I., Pannemans, J., & Tack, J. F. (2020) · Minerva Gastroenterologica e Dietologica · doi:10.23736/s1121-421x.19.02640-0 · Cited by 49
Brenner, D., Argoff, C., Fox, S., Bochenek, W., D'Astoli, P., Blakesley, R., Reasner, D., O'Dea, C. R., & Cash, B. (2020) · Pain · doi:10.1097/j.pain.0000000000001754 · Cited by 11
Pohl, D., Fried, M., Lawrance, D., Beck, E., & Hammer, H. F. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025627 · Cited by 7
Self-citationTreatment of Irritable Bowel Syndrome Using Fecal Microbiota Transplantation: A Step Forward?
Camilleri, M., & Dilmaghani, S. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.087 · Cited by 8
Metadata
- Authors
- Yiannakou, Y., Agrawal, A., Allen, P. B., Arebi, N., Brown, S. R., Eugenicos, M. P., Farmer, A. D., McLain-Smith, S., McLaughlin, J., Sanders, D. S., Lawrance, D., & Emmanuel, A.
- Affiliations
- County Durham and Darlington NHS Foundation Trust (GB)
- Doncaster Royal Infirmary (GB)
- South Eastern Health and Social Care Trust (GB)
- London North West Healthcare NHS Trust (GB)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- NHS Lothian (GB)
- University Hospitals of North Midlands NHS Trust (GB)
- pH Associates Ltd, Marlow, UK
- Manchester Academic Health Science Centre (GB)
- Allergan (United Kingdom) (GB)
- University College Hospital (GB)
- Corresponding author
- Yiannakou, Yan
- ORCID
- Venue
- Therapeutic Advances in Gastroenterology
- Publisher
- SAGE Publications
- Published
- 2018-01
- Volume
- 11
- Pages
- 1756284818798791-1756284818798791
- ISSN
- 1756-283X (ISSN-L)
- 1756-2848
- PMC
- PMC6170957
- OpenAlex
- W2894886573
- Cited by
- 12
- References
- 32
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 1
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Gastroenterology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by-nc)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Allergan plc.
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- linaclotide, irritable bowel syndrome with constipation, guanylate cyclase-C agonist, symptom severity, real-world outcomes, adverse events, diarrhea, laxative use, long-term treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. https://app.cochat.ai/papers/10.1177/1756284818798791
- The paper
- Yiannakou, Y., Agrawal, A., Allen, P. B., Arebi, N., Brown, S. R., Eugenicos, M. P., Farmer, A. D., McLain-Smith, S., McLaughlin, J., Sanders, D. S., Lawrance, D., & Emmanuel, A. (2018). UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756284818798791
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.